CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionDebt-to-equity is 3.49×, higher than 95% of its Biotechnology peers (median 0.07×)
- FinancialsAltman Z-Score -2.92: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
488.50MUSDvs all stocks (USD)
Revenue (TTM)
174.48MUSDvs all stocks (USD)
Profit Margin
-112.58%vs Biotechnology peers
Beta
0.9330xvs all stocks
52-Week Change
-24.87%vs all stocks
Market Capitalization
488.50MUSDvs all stocks (USD)
Enterprise Value
633.44MUSDvs all stocks (USD)
Forward P/E
-2.46xvs Biotechnology peers
Price to Sales (TTM)
2.80xvs Biotechnology peers
Price to Book (MRQ)
5.58xvs Biotechnology peers
Enterprise to Revenue
3.63xvs Biotechnology peers
Enterprise to EBITDA
-4.26xvs Biotechnology peers
Gross Margin
99.04%vs Biotechnology peers
Profit Margin
-112.58%vs Biotechnology peers
Return on Assets (TTM)
-21.20%vs Biotechnology peers
Return on Equity (TTM)
-137.63%vs Biotechnology peers
Revenue (TTM)
174.48MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.34USDUpdated Sep 28, 2026Quarterly Revenue Growth
405.70%vs Biotechnology peers
Gross Profit (TTM)
-78.42MUSDvs all stocks (USD)
EBITDA (TTM)
-148.78MUSDvs all stocks (USD)
Net Income (TTM)
-196.43MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
405.73%vs Biotechnology peers
Operating Cash Flow (TTM)
-246.67MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-184.26MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
170.44MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
20.30MUSDFY2025 · Dec 31, 2025Gross Profit
150.14MUSDFY2025 · Dec 31, 2025Operating Income
-161.20MUSDvs all stocks (USD)
Pre-tax Income
-193.88MUSDFY2025 · Dec 31, 2025Net Income
-193.88MUSDFY2025 · Dec 31, 2025EBIT
-148.87MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-145.50MUSDFY2025 · Dec 31, 2025Research & Development
228.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
82.86MUSDFY2025 · Dec 31, 2025Other Operating Expenses
179.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
83.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
45.01MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-193.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-115.79MUSDFY2025 · Dec 31, 2025Free Cash Flow
-118.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 15.62M of depreciation against 2.41M of capital expenditure, and its own free-cash-flow line reads -126.38M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
36.50MUSDFY2025 · Dec 31, 2025Income Tax Paid
285.00KUSDFY2025 · Dec 31, 2025Interest Paid
32.11MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-193.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
15.62MUSDFY2025 · Dec 31, 2025Stock-based Compensation
34.56MUSDFY2025 · Dec 31, 2025Other Non-cash Items
13.50MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.66MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
24.36MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.41MUSDFY2025 · Dec 31, 2025Purchase of Investments
-332.63MUSDFY2025 · Dec 31, 2025Sale of Investments
319.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-15.87MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
144.49MUSDFY2025 · Dec 31, 2025Other Financing Charges
-29.09MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
116.45MUSDFY2025 · Dec 31, 2025Shares Outstanding
54.16MSharesUpdated Sep 28, 2026Shares Short
7.93MSharesUpdated Sep 28, 2026Short Ratio
5.97daysvs all stocks
Short % of Shares Outstanding
12.71%vs all stocks
% Held by Insiders
6.55%vs all stocks
% Held by Institutions
65.72%vs all stocks
Total Cash (MRQ)
105.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.60USDUpdated Sep 28, 2026Total Debt (MRQ)
250.46MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.49xvs Biotechnology peers
Current Ratio (MRQ)
2.86xvs Biotechnology peers
Book Value per Share (MRQ)
1.32USDUpdated Sep 28, 2026Total Assets
453.03MUSDvs all stocks (USD)
Total Current Assets
281.28MUSDFY2025 · Dec 31, 2025Total Liabilities
350.30MUSDFY2025 · Dec 31, 2025Total Non-current Assets
171.75MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
232.20MUSDFY2025 · Dec 31, 2025Total Current Liabilities
118.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
34.47MUSDFY2025 · Dec 31, 2025Other Short-term Investments
195.60MUSDFY2025 · Dec 31, 2025Accounts Receivable
557.00KUSDFY2025 · Dec 31, 2025Accounts Payable
21.36MUSDFY2025 · Dec 31, 2025Short-term Debt
8.29MUSDFY2025 · Dec 31, 2025Deferred Revenue
10.45MUSDFY2025 · Dec 31, 2025Other Current Liabilities
39.61MUSDFY2025 · Dec 31, 2025Long-term Debt
65.22MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
148.05MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.13BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
102.73MUSDvs all stocks (USD)
52-Week Low
5.46USDUpdated Sep 28, 202652-Week High
16.19USDUpdated Sep 28, 202652-Week Change
-24.87%vs all stocks
Beta
0.9330xvs all stocks
50-Day MA
9.55USDUpdated Sep 28, 2026200-Day MA
10.02USDUpdated Sep 28, 2026Avg 10-Day Volume
1.49MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.38MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.78USDUpdated Sep 28, 2026Other Income / Expense
12.24MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 3.49×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 3.49Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.99Profit Margin: -1.13
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.86Altman Z-Score: -2.92
Financial Health
Altman Z-Score -2.92: distress zoneCritical
Altman Z-Score: -2.92
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Capricor Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chison Medical Technologies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanhua Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onconic Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Bakkt Holdings, Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
BALLARD POWER SYSTEMS INC Common Stock
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Bitdeer Technologies Group
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated